SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Iannettoni MD. Staging strategies for lung cancer. JAMA. 2010;304:2296-2297.
  • 2
    NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non–small cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol. 2008;26:4617-4625.
  • 3
    Davidoff AJ, Tang M, Seal B, Edelman MJ. Chemotherapy and survival benefit in elderly patients with advanced non–small cell lung cancer. J Clin Oncol. 2010;28:2191-2197.
  • 4
    The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non–small cell lung cancer. J Natl Cancer Inst. 1999;91:66-72.
  • 5
    Quoix E, Zalcman G, Oster JP, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non–small cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet. 2011;378:1079-1088.
  • 6
    Goffin J, Lacchetti C, Ellis PM, Ung YC, Evans WK; Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care. First-line systemic chemotherapy in the treatment of advanced non–small cell lung cancer: a systematic review. J Thorac Oncol. 2010;5:260-274.
  • 7
    Baggstrom MQ, Stinchcombe TE, Fried DB, Poole C, Hensing TA, Socinski MA. Third-generation chemotherapy agents in the treatment of advanced non–small cell lung cancer: a meta-analysis. J Thorac Oncol. 2007;2:845-853.
  • 8
    Langer CJ, Leighton JC, Comis RL, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non–small cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol. 1995;13:1860-1870.
  • 9
    Lilenbaum RC, Herndon JE, 2nd, List MA, et al. Single-agent versus combination chemotherapy in advanced non–small cell lung cancer: the Cancer and Leukemia Group B (study 9730). J Clin Oncol. 2005;23:190-196.
  • 10
    Schiller JH, Harrington D, Belani CP, et al. Comparison of 4 chemotherapy regimens for advanced non–small cell lung cancer. N Engl J Med. 2002;346:92-98.
  • 11
    Le Chevalier T, Scagliotti G, Natale R, et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non–small cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer. 2005;47:69-80.
  • 12
    Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing 3 platinum-based doublets in advanced non–small cell lung cancer. J Clin Oncol. 2002;20:4285-4291.
  • 13
    Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non–small cell lung cancer: the TAX 326 Study Group. J Clin Oncol. 2003;21:3016-3024.
  • 14
    Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non–small cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001;19:3210-3218.
  • 15
    Treat JA, Gonin R, Socinski MA, et al. A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non–small cell lung cancer. Ann Oncol. 2010;21:540-547.
  • 16
    Helbekkmo N, Sundstrm SH, Aasebo U, et al. Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer. 2007;97:283-289.
  • 17
    Belani CP, Lee JS, Socinski MA, et al. Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non–small cell lung cancer. Ann Oncol. 2005;16:1069-1075.
  • 18
    Ritzwoller DP, Carroll NM, Delate T, et al. Patterns and predictors of first-line chemotherapy use among adults with advanced non–small cell lung cancer in the cancer research network. Lung Cancer. 2012;78:245-252.
  • 19
    Zhu J, Sharma D, Gray SW, Chen AB, Weeks JC, Schrag D. Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non–small cell lung cancer. JAMA. 2012;307:1593-1601.
  • 20
    Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non–small cell lung cancer. J Clin Oncol. 2008;26:3543-3551.
  • 21
    Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of 2 Phase III studies. Oncologist. 2009;14:253-263.
  • 22
    Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non–small cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009;374:1432-1440.
  • 23
    Treat J, Edelman MJ, Belani CP, et al. A retrospective analysis of outcomes across histological subgroups in a 3-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non–small cell lung cancer. Lung Cancer. 2010;70:340-346.
  • 24
    Scagliotti G, Brodowicz T, Shepherd FA, et al. Treatment-by-histology interaction analyses in 3 phase III trials show superiority of pemetrexed in nonsquamous non–small cell lung cancer. J Thorac Oncol. 2011;6:64-70.
  • 25
    National Cancer Institute. Surveillance, Epidemiology, and End Results. Available at: http://seer.cancer.gov. Accessed July 1, 2012.
  • 26
    Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40:IV-3-IV-18.
  • 27
    National Cancer Institute. SEER-Medicare: Medicare Claims Files. Available at: http://healthservices.cancer.gov/seermedicare/medicare/claims.html. Accessed July 1, 2012.
  • 28
    Greene FL, Page DL, Fleming ID, Balch CM; American Joint Committee on Cancer (AJCC). AJCC Cancer Staging Handbook. 6th ed. New York: Springer; 2002.
  • 29
    Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002;40:IV-55-IV-61.
  • 30
    Lamont EB, Herndon JE 2nd, Weeks JC, et al. Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants. J Natl Cancer Inst. 2005;97:1080-1083.
  • 31
    Bach PB, Guadagnoli E, Schrag D, Schussler N, Warren JL. Patient demographic and socioeconomic characteristics in the SEER-Medicare database: applications and limitations. Med Care. 2002;40:IV-19-IV-25.
  • 32
    Fritz AG, Percy C, Jack A, et al., eds. International Classification of Diseases for Oncology (ICD-O). 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
  • 33
    Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6:244-285.
  • 34
    Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
  • 35
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
  • 36
    Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53:1258-1267.
  • 37
    Klabunde CN, Legler JM, Warren JL, Baldwin LM, Schrag D. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol. 2007;17:584-590.
  • 38
    Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41-55.
  • 39
    Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc. 1984;79:516-524.
  • 40
    D'Agostino RB Jr, D'Agostino RB Sr. Estimating treatment effects using observational data. JAMA. 2007;297:314-316.
  • 41
    Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127:757-763.
  • 42
    D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a nonrandomized control group. Stat Med. 1998;17:2265-2281.
  • 43
    Lunceford JK, Davidian M. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Stat Med. 2004;23:2937-2960.
  • 44
    Robins JM, Herna MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11:550-560.
  • 45
    Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non–small cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007;99:847-857.
  • 46
    Jiang J, Liang X, Zhou X, Huang R, Chu Z. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non–small cell lung cancer. Lung Cancer. 2007;57:348-358.
  • 47
    Belani CP, Ramalingam S, Perry MC, et al. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non–small cell lung cancer. J Clin Oncol. 2008;26:468-473.
  • 48
    Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non–small cell lung cancer: final results of a phase III trial. J Clin Oncol. 2012;30:2055-2062.
  • 49
    Groen HJ, Sietsma H, Vincent A, et al. Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non–small cell lung cancer: the NVALT-4 study. J Clin Oncol. 2011;29:4320-4326.
  • 50
    Booton R, Lorigan P, Anderson H, et al. A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non–small cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1). Ann Oncol. 2006;17:1111-1119.
  • 51
    Clements KM, Peltz G, Faries DE, et al. Does type of tumor histology impact survival among patients with stage IIIB/IV non–small cell lung cancer treated with first-line doublet chemotherapy [serial online]? Chemother Res Pract 2010: 524629, 2010.
  • 52
    Treat J, Scagliotti GV, Peng G, Monberg MJ, Obasaju CK, Socinski MA. Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non–small cell lung cancer (NSCLC): a combined analysis of 3 phase 3 trials. Lung Cancer. 2012;76:222-227.
  • 53
    West L, Vidwans SJ, Campbell NP, et al. A novel classification of lung cancer into molecular subtypes [serial online]. PLoS One. 2012;7:e31906.
  • 54
    Howlader N, Noone AM, Krapcho M, et al., eds. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations) [based on November 2011 SEER data submission, posted to the SEER web site, April 2012]. Bethesda, MD: National Cancer Institute; 2012. Available at: http://seer.cancer.gov/csr/1975_2009_pops09/. Accessed July 1, 2012.